Filing Flows › Biotricity (BTCY) › Q3 FY26
Biotricity (BTCY) Q3 FY26 earnings results (third quarter fiscal 2026)
10-Q filed Feb 11, 2026
Biotricity (BTCY) reported revenue of $4.0M for the third quarter fiscal 2026 (Q3 FY26), +10% from a year earlier and +3% from the quarter before. Operating margin was 11.1%, net loss $717K (18.0% of revenue).
Biotricity, Q3 FY26: revenue $4.0M (+10% year over year), operating margin 11.1%, net loss $717K, operating cash flow −$740K. The chart follows the revenue to costs, profit and cash.
| Q3 FY26 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $4.0M | +3% | +10% |
| Operating profit | $441K | +61% | — |
| Net earnings | −$717K | — | — |
| Operating cash flow | −$740K | -278% | — |
What changed
Revenue was $4.0M in Q3 FY26, up 10% year over year and up 3% from the previous quarter. Technology Fees was the largest line at 91% of revenue. Technology Fees added $250K year over year (up 7%), 68% of the total change.
Gross margin was 81.5%, up 5.2 points from Q3 FY25. Operating profit was $441K, a 11.1% margin (up 15.7 points year over year). Operating expenses fell 4% while revenue rose 10%. The fastest-growing cost line was Research & development (+13%). The quarter ended with a net loss of $717K, wider than the previous quarter's $691K loss. Net interest and other expense of $1.2M was the main reason.
Operating cash flow was −$740K. Non-cash charges added back $1K of depreciation and $6K of share-based compensation.
Questions
What was Biotricity's revenue in the third quarter fiscal 2026?
Biotricity (BTCY) reported revenue of $4.0M for the third quarter fiscal 2026 (Q3 FY26), +10% from a year earlier and +3% from the quarter before.
Was Biotricity profitable in the third quarter fiscal 2026?
Operating profit was $441K (11.1% of revenue) and net loss $717K.
Source: Biotricity 10-Q on SEC EDGAR.